Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05026606
Title Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

ovarian clear cell carcinoma

peritoneum cancer

fallopian tube cancer

Therapies

Etigilimab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.